|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Multicentered prospective investigator initiated study to evaluate the clinical outcomes with extracorporeal cytokine adsorption device (CytoSorb®) in patients with sepsis and septic shock显示文摘BACKGROUND Sepsis is a severe clinical syndrome related to the host response to infection.The severity of infections is due to an activation cascade that will lead to an auto amplifying cytokine production:The cytokine storm.Hemoadsorption by CytoSorb®therapy is a new technology that helps to address the cytokine storm and to regain control over various inflammatory conditions.AIM To evaluate prospectively CytoSorb®therapy used as an adjunctive therapy along with standard of care in septic patients admitted to intensive care unit(ICU).METHODS This was a prospective,real time,investigator initiated,observational multicenter study conducted in patients admitted to the ICU with sepsis and septic shock.The improvement of mean arterial pressure and reduction of vasopressor needs were evaluated as primary outcome.The change in laboratory parameters,sepsis scores[acute physiology and chronic health evaluation(APACHE II)and sequential organ failure assessment(SOFA)]and vital parameters were considered as secondary outcome.The outcomes were also evaluated in the survivor and nonsurvivor group.Descriptive statistics were used;a P value<0.05 was considered RESULTS Overall,45 patients aged≥18 and≤80 years were included;the majority were men(n=31;69.0%),with mean age 47.16±14.11 years.Post CytoSorb®therapy,26 patients survived and 3 patients were lost to follow-up.In the survivor group,the percentage dose reduction in vasopressor was norepinephrine(51.4%),epinephrine(69.4%)and vasopressin(13.9%).A reduction in interleukin-6 levels(52.3%)was observed in the survivor group.Platelet count improved to 30.1%(P=0.2938),and total lung capacity count significantly reduced by 33%(P<0.0001).Serum creatinine and serum lactate were reduced by 33.3%(P=0.0190)and 39.4%(P=0.0120),respectively.The mean APACHE II score was 25.46±2.91 and SOFA scores was 12.90±4.02 before initiation of CytoSorb®therapy,and they were reduced significantly post therapy(APACHE II 20.1±2.47;P<0.0001 and SOFA 9.04±3.00;P=0.0003)in the survivor group.The predicted mortality in our patient population before CytoSorb®therapy was 56.5%,and it was reduced to 48.8%(actual mortality)after CytoSorb®therapy.We reported 75%survival rate in patients given treatment in<24 h of ICU admission and 68%survival rates in patients given treatment within 24-48 h of ICU admission.In the survivor group,the average number of days spent in the ICU was 4.44±1.66 d;while in the nonsurvivor group,the average number of days spent in ICU was 8.5±15.9 d.CytoSorb®therapy was safe and well tolerated with no adverse events reported.CONCLUSION CytoSorb®might be an effective adjuvant therapy in stabilizing sepsis and septic shock patients.However,it is advisable to start the therapy at an early stage(preferably within 24 h after onset of septic shock). | Rajib Paul Prachee Sathe Senthil Kumar Shiva Prasad Ma Aleem Prashant Sakhalvalkar | 2021 | World Journal of Critical Care Medicine2021，10，1： | 2 |
| 2 | Computational prediction and experimental verification of novel ldeR binding sites in the upstream of Mycobacterium tuberculosis open reading frames显示文摘 | PRAKASH Prachee YELLABOINA Sailu RANJAN Aash | 2005 | Bioinformatics2005，21，10： | 1 |
| 3 | Computational prediction and experimental verification of novel IdeR binding sites in the upstream sequences of mycobacterium tuberculosis open reading frames显示文摘 | Prachee P Sailu Y Akash R | | 0，，10： | 1 |
| 4 | A conceptual framework for comparing instructional design models显示文摘 | Gerald S. Edmonds Robert C. Branch Prachee Mukherjee | 1994 | Educational Technology Research and Development1994，，4： | 1 |
| 5 | Prediction of State Transitions in Rayleigh Fading Chan-nels显示文摘 | Prachee Sharma Kavitha Chandra | 2007 | Ieee transactions on vehicular tech-nology2007，56，2： | 1 |
| 6 | Developing a diet authentication system from the composition of milk and meat in sheep:a review显示文摘 | PRACHE S | | 0，，05： | 1 |
| 7 | Prediction of state transitions in Rayleigh fading channels显示文摘 | Prachee S Kavitha C | 2007 | IEEE Trans Vehicular Technology2007，56，2： | 1 |
| 8 | Developing a diet authentication system from the composition of milk and meat in sheep:a review显示文摘 | PRACHE S | | 0，，05： | 1 |
| 9 | Active matrix molecular OLED microdisplays显示文摘 | O Prache | 2001 | Displays2001，，2： | 1 |
| 10 | Comparison of visible and near infrared reflectance spectroscopy to discriminate between pasture-fed and concentrate-fed lamb carcasses显示文摘 | P.H.M. Dian D. Andueza M. Jestin I.N. Prado S. Prache | 2008 | Meat Science2008，，4： | 1 |
| 11 | Traceability of animal feeding diet in the meat and milk of small ruminants显示文摘 | S. Prache A. Cornu J.L. Berdagué A. Priolo | 2005 | Small Ruminant Research2005，，2： | 1 |
| 12 | Systematic review with expert consensus on use of extracorporeal hemoadsorption in septic shock:An Indian perspective显示文摘BACKGROUND Septic shock is a severe form of sepsis characterised by deterioration in circulatory and cellular-metabolic parameters.Despite standard therapy,the outcomes are poor.Newer adjuvant therapy,such as CytoSorb®extracorporeal haemoadsorption device,has been investigated and shown promising outcome.However,there is a lack of some guidance to make clinical decisions on the use of CytoSorb®haemoadsorption as an adjuvant therapy in septic shock in Indian Setting.Therefore,this expert consensus was formulated.AIM To formulate/establish specific consensus statements on the use of CytoSorb®haemoadsorption treatment based on the best available evidence and contextualised to the Indian scenario.METHODS We performed a comprehensive literature on CytoSorb®haemoadsorption in sepsis,septic shock in PubMed selecting papers published between January 2011 and March 20232021 in English language.The statements for a consensus document were developed based on the summarised literature analysis and identification of knowledge gaps.Using a modified Delphi approach combining evidence appraisal and expert opinion,the following topics related to CytoSorb®in septic shock were addressed:need for adjuvant therapy,initiation timeline,need for Interleukin-6 levels,duration of therapy,change of adsorbers,safety,prerequisite condition,efficacy endpoints and management flowchart.Eleven expert members from critical care,emergency medicine,and the intensive care participated and voted on nine statements and one open-ended question.RESULTS Eleven expert members from critical care,emergency medicine,and the intensive care participated and voted on nine statements and one open-ended question.All 11 experts in the consensus group(100%)participated in the first,second and third round of voting.After three iterative voting rounds and adapting two statements,consensus was achieved on nine statements out of nine statements.The consensus expert panel also recognised the necessity to form an association or society that can keep a registry regarding the use of CytoSorb®for all indications in the open-ended question(Q10)focusing on“future recommendations for CytoSorb®therapy”.CONCLUSION This Indian perspective consensus statement supports and provides guidance on the use of CytoSorb®haemoadsorption as an adjuvant treatment in patients with septic shock to achieve optimal outcomes. | Yatin Mehta Abdul Samad Ansari Amit Kumar Mandal Dipanjan Chatterjee Gauri Shankar Sharma Prachee Sathe Purvesh V Umraniya Rajib Paul Sachin Gupta Vinod Singh Yogendra Pal Singh | 2024 | World Journal of Critical Care Medicine2024，13，1： | 0 |
| 13 | Extracorporeal blood purification strategies in sepsis and septic shock:An insight into recent advancements显示文摘BACKGROUND Despite various therapies to treat sepsis,it is one of the leading causes of mortality in the intensive care unit patients globally.Knowledge about the pathophysiology of sepsis has sparked interest in extracorporeal therapies(ECT)which are intended to balance the dysregulation of the immune system by removing excessive levels of inflammatory mediators.AIM To review recent data on the use of ECT in sepsis and to assess their effects on various inflammatory and clinical outcomes.METHODS In this review,an extensive English literature search was conducted from the last two decades to identify the use of ECT in sepsis.A total of 68 articles from peer-reviewed and indexed journals were selected excluding publications with only abstracts.RESULTS Results showed that ECT techniques such as high-volume hemofiltration,coupled plasma adsorption/filtration,resin or polymer adsorbers,and CytoSorb®are emerging as adjunct therapies to improve hemodynamic stability in sepsis.CytoSorb®has the most published data in regard to the use in the field of septic shock with reports on improved survival rates and lowered sequential organ failure assessment scores,lactate levels,total leucocyte count,platelet count,interleukin-IL-6,IL-10,and TNF levels.CONCLUSION Clinical acceptance of ECT in sepsis and septic shock is currently still limited due to a lack of large random clinical trials.In addition to patient-tailored therapies,future research developments with therapies targeting the cellular level of the immune response are expected. | Yatin Mehta Rajib Paul Abdul Samad Ansari Tanmay Banerjee Serdar Gunaydin Amir Ahmad Nassiri Federico Pappalardo Vedran Premužić Prachee Sathe Vinod Singh Emilio Rey Vela | 2023 | World Journal of Critical Care Medicine2023，12，2： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员